Clinical Trials Logo

Clinical Trial Summary

PD1 blockade has been approved as salvage therapy for advanced hepatocellular carcinoma (HCC). Although there is not solid evidence that PD1 blockade would induce hepatitis B virus (HBV) reactivation, previous clinical trials of PD1 blockade required enrolled patients to receive anti-HBV medications and control the viral load to be under 100-2000 IU/mL before initiation of PD1 blockade therapy. Such a requirement may not be necessary and could delay the treatment. Guidelines for prevention of chemotherapy induced HBV reactivation only suggest combining anti-HBV medications during the chemotherapy course without such a requirement of very load HBV viral load. The investigators hypothesized that under anti-HBV medications, patients with advanced HCC and active chronic hepatitis B virus (HBV) infection can receive durvalumab treatment without increased risks of HBV reactivation and related complications.


Clinical Trial Description

Although durvalumab has not been approved as treatment for HCC, similar PD1 blockade agents such as nivolumab and pembrolizumab have gain approval as salvage therapy for advanced HCC. The investigators will enroll 43 patients with active (defined as serum viral load > 2000 IU/mL) chronic HBV infection (defined as positive serum HBV surface antigen). All patients would receive entecavir within 7 days of initiation of durvalumab treatment. Durvalumab 1500 mg would be given intravenously every 4 weeks until confirmed disease progression, intolerable side effects, or completion of 24 treatment. Tumor assessment will be performed every 8-12 weeks. HBV viral load will be monitored at least once per month. Entecavir treatment will be continued at least 6 months after discontinuation of durvalumab treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04294498
Study type Interventional
Source National Taiwan University Hospital
Contact Yu-Yun Shao, MD, PhD
Phone +886972651777
Email yuyunshao@gmail.com
Status Recruiting
Phase Phase 2
Start date November 2, 2020
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Recruiting NCT05057845 - Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma Phase 2
Recruiting NCT02638857 - Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT02632006 - Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT00752063 - Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma Phase 2
Completed NCT00517920 - Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) Phase 2
Recruiting NCT05797805 - A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Active, not recruiting NCT05070156 - B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma Early Phase 1
Not yet recruiting NCT06092112 - A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma Early Phase 1
Recruiting NCT01214343 - Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC Phase 3
Completed NCT00999882 - Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients Phase 1
Withdrawn NCT00756782 - A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma Phase 2
Completed NCT00534664 - Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT04503902 - Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Terminated NCT04777708 - BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer Early Phase 1
Completed NCT04072679 - Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma Phase 1
Suspended NCT04066660 - Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC) N/A
Withdrawn NCT05592197 - Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT N/A
Completed NCT02528643 - A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma Phase 2
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1